NXPH4 and esophageal cancer: A pan-cancer analysis demonstrated the consistent upregulation of NXPH4 across various DSCs, suggesting its diagnostic potential in cholangiocarcinoma, esophageal cancer, liver cancer, and gastric cancer (Fig. S1).